Captrust Financial Advisors Buys 7,969 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Captrust Financial Advisors boosted its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 84.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,394 shares of the specialty pharmaceutical company's stock after purchasing an additional 7,969 shares during the quarter. Captrust Financial Advisors' holdings in Supernus Pharmaceuticals were worth $629,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Smartleaf Asset Management LLC raised its stake in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after purchasing an additional 870 shares in the last quarter. Mark Sheptoff Financial Planning LLC purchased a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $52,000. Headlands Technologies LLC raised its stake in shares of Supernus Pharmaceuticals by 203.0% during the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock worth $55,000 after acquiring an additional 1,015 shares in the last quarter. Newbridge Financial Services Group Inc. purchased a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $72,000. Finally, Venturi Wealth Management LLC purchased a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $92,000.

Supernus Pharmaceuticals Stock Up 0.2%

Shares of Supernus Pharmaceuticals stock traded up $0.06 on Friday, hitting $32.10. The stock had a trading volume of 330,988 shares, compared to its average volume of 483,604. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $40.28. The stock has a market cap of $1.80 billion, a price-to-earnings ratio of 30.00 and a beta of 0.74. The stock's 50-day simple moving average is $31.98 and its two-hundred day simple moving average is $34.77.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Cantor Fitzgerald reissued a "neutral" rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, May 16th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.